Cancer Grand Challenges launches global consultation to find cancer’s toughest challenges

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Cancer Grand Challenges, a funding initiative co-founded by Cancer Research UK and NCI, brings together a community of diverse, world-class researchers to tackle cancer’s toughest challenges. Researchers, patient advocates, and the public are invited to submit ideas to shape its next round of funding and to help drive vital progress against cancer.

The submission portal opened Oct. 24, and closes Nov. 28. More information and submission page can be found here.

The final shortlisted challenges will be announced in March 2023, with teams invited to apply for $25 million in funding.

“Cancer Grand Challenges aims to identify challenges that truly capture the imagination of the research community and then, to make progress against them. But we need input and ideas from across the world,” professor Sir David Lane, chair of the Cancer Grand Challenges Scientific Committee, said in a statement. “Issuing this public call for submissions for ideas around the toughest challenges in cancer research, will help to shape our next round of funding.”

The challenge consultation aims to identify a selection of challenges which, if solved, could revolutionize how we approach the disease. This is a unique opportunity to shape cancer research funding on a global scale. In addition to Cancer Research UK and the NCI, other partners for round three of the initiative include the Mark Foundation for Cancer Research and the Spanish Association Against Cancer.

Cancer grand challenges can be problems relevant to understanding, preventing, detecting or treating cancer. These problems could be new, such as understanding the potential benefits and risks of e-cigarettes, or be problems that have existed for decades such as understanding the link between inflammation and cancer,” David Scott, director of Cancer Grand Challenges, said in a statement.

Table of Contents

YOU MAY BE INTERESTED IN

Login